Insights Into Multiple Myeloma (MM)

Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents

Florida – February 9, 2024

Faculty Chair

Melissa Alsina, MD

Moffitt Cancer Center, Tampa, FL, USA

Central – April 20, 2024

Faculty Chair

Hans Lee, MD

MD Anderson Cancer Center, Houston, TX, USA

Nebraska – June 29, 2024

Faculty Co-Chair

Sarah A. Holstein, MD, PhD

University of Nebraska Medical Center, Omaha, NE, USA

Faculty Co-Chair

David Dingli, MD

Mayo Clinic, Rochester, MN, USA

Northeast – August 24, 2024

Faculty Chair

Saad Usmani, MD, FACP, FASCO

Sloan Kettering Cancer Center, New York, NY, USA

Midwest – September 21, 2024

Faculty Chair

Binod Dhakal, MD

Medical College of Wisconsin, Milwaukee, WI, USA

California – October 11, 2024

Faculty Chair

Murali Janakiram, MD

City of Hope, Duarte, CA, USA

More Information

  • Tampa, FL
  • Florida

More Information

  • Dallas, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • San Diego, CA
  • California

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of MM
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.